首页 > 最新文献

International Journal of Gynecologic Cancer最新文献

英文 中文
Reviews covering publications from September 30, 2022–March 31, 2023 对 2022 年 9 月 30 日至 2023 年 3 月 31 日期间的出版物进行审查
Pub Date : 2024-06-01 DOI: 10.1136/ijgc-34-s2
{"title":"Reviews covering publications from September 30, 2022–March 31, 2023","authors":"","doi":"10.1136/ijgc-34-s2","DOIUrl":"https://doi.org/10.1136/ijgc-34-s2","url":null,"abstract":"","PeriodicalId":13983,"journal":{"name":"International Journal of Gynecologic Cancer","volume":"447 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141401452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reviews covering publications from March 31, 2020 – September 30, 2020 评审涵盖2020年3月31日至2020年9月30日期间的出版物
Pub Date : 2021-01-01 DOI: 10.1136/ijgc-31-s1
K. Lindemann, K. Zalewski, K. J. Halaska, Z. Razumova
{"title":"Reviews covering publications from March 31, 2020 – September 30, 2020","authors":"K. Lindemann, K. Zalewski, K. J. Halaska, Z. Razumova","doi":"10.1136/ijgc-31-s1","DOIUrl":"https://doi.org/10.1136/ijgc-31-s1","url":null,"abstract":"","PeriodicalId":13983,"journal":{"name":"International Journal of Gynecologic Cancer","volume":"12 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87047723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reviews covering publications from September 30, 2019 - March 31, 2020 评论涵盖2019年9月30日至2020年3月31日的出版物
Pub Date : 2020-07-01 DOI: 10.1136/ijgc-30-s2
{"title":"Reviews covering publications from September 30, 2019 - March 31, 2020","authors":"","doi":"10.1136/ijgc-30-s2","DOIUrl":"https://doi.org/10.1136/ijgc-30-s2","url":null,"abstract":"","PeriodicalId":13983,"journal":{"name":"International Journal of Gynecologic Cancer","volume":"47 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85433206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
17th Biennial Meeting of the International Gynecologic Cancer Society Kyoto, Japan September 14-16, 2018 第17届国际妇科癌症学会双年会议,日本京都,2018年9月14-16日
Pub Date : 2018-09-01 DOI: 10.1097/01.IGC.0000546279.09648.02
P. Cohen, S. Böhm, A. Powell, T. Meniawy, C. Stewart, Max K. Bulsara, C. Gilks, N. Singh
Clinical medicine hopes for the development of reliable tumor markers, on the basis of which there can be chosen the optimal treatment program for uterine sarcoma patients, and also make a prognosis. The hyperexpression of PD-L1 in different tumors such as melanoma, kidney cancer, non-small cell lung cancer correlates with unfavorable prognosis of the disease. The role of PD-L1 expression, as a tumor marker in sarcoma, remains unclear. Objective. The investigation of PD-L1 expression as a prognostic tumor marker for uterine sarcoma. Methods. There have been selected 30 uterine sarcoma patients stage I-II (T1-2NxM0), for immunohistochemistry analyze of PD-L1 expression. Depending on the morphological tumor types all the patients were distributed: leiomyosarcoma (LMS) 20.0%, endometrial stromal sarcoma (ESS) 46.7%, undifferentiated sarcoma (HC) 33.3%. Results. Our results showed that 73.3 % of patients with uterine sarcoma showed a low expression level of PD-L1. The moderate level and overexpression of PD-L1 were observed in the undifferentiated and endometrial stromal sarcoma (fig.1) – in 13.3 and 6.7 %, respectively. At further follow-up of patients with PD-L1 expression, the relapse of the disease was detected in 50.0 % of cases. Conclusion. The PD-L1 expression in tumor tissue, regardless of its level, is considered to be an unfavorable prognostic factor for the uterine sarcoma patients. In case of moderate expression level of PD-L1, so as at its overexpression, the tumor progression was detected in 83.3% of uterine sarcoma patients. Fig.1. Moderate expression level of PD-L1 in ESS cells. Reaction from MCAB to PD-L1 (Clone 130021), х400. Copyright ' 2018 by IGCS and ESGO. Unauthorized reproduction of this article is prohibited. 569 Volume 28, Supplement 2, September 2018 POSTER PRESENTATIONS Gynecologic Pathology/Cytology and Disease Pathogenesis IGCS8-0522 RAS GENES IS FREQUENTLY MUTATED IN ENDOMETRIAL POLYPS T. Takeda, K. Banno, M. Yanokura, T. Takahashi, M. Anko, A. Sera, H. Kunitomi, K. Tsuji, Y. Kobayashi, E. Tominaga, D. Aoki Keio University School of Medicine, Obstetrics and Gynecology, Tokyo, Japan Background and Aims: Endometrial polyp is a common disease for women in reproductive age, however a molecular mechanism of endometrial polyp is still unclear. Next-generation sequencer makes whole exome sequencing easier. In this study, we investigated a driver gene of endometrial polyp by next-generation sequencer.
临床医学希望开发可靠的肿瘤标志物,在此基础上为子宫肉瘤患者选择最佳的治疗方案,并进行预后判断。PD-L1在黑色素瘤、肾癌、非小细胞肺癌等不同肿瘤中的高表达与疾病的不良预后相关。PD-L1表达作为肿瘤标志物在肉瘤中的作用尚不清楚。目标。PD-L1表达作为子宫肉瘤预后肿瘤标志物的研究。方法。选取30例I-II期(T1-2NxM0)子宫肉瘤患者,进行PD-L1表达免疫组化分析。根据肿瘤的形态类型,所有患者的分布:平滑肌肉瘤(LMS)占20.0%,子宫内膜间质肉瘤(ESS)占46.7%,未分化肉瘤(HC)占33.3%。结果。结果显示,73.3%的子宫肉瘤患者PD-L1表达水平较低。在未分化和子宫内膜间质肉瘤中,PD-L1的中表达和过表达分别为13.3%和6.7%(图1)。在PD-L1表达患者的进一步随访中,50.0%的病例检测到疾病复发。结论。PD-L1在肿瘤组织中的表达,无论其水平如何,都被认为是子宫肉瘤患者预后的不利因素。在PD-L1表达水平适中的情况下,当PD-L1过表达时,83.3%的子宫肉瘤患者发现肿瘤进展。图1。PD-L1在ESS细胞中表达水平中等。MCAB对PD-L1(克隆130021)的反应,х400。IGCS和ESGO版权所有。未经授权,禁止转载本文。妇科病理/细胞学和疾病发病机制IGCS8-0522 RAS基因在子宫内膜息肉中经常发生突变T. Takeda, K. Banno, M. Yanokura, T. Takahashi, M. Anko, A. Sera, H. Kunitomi, K. Tsuji, Y. Kobayashi, E. Tominaga, D.青木庆应大学医学院,妇产科,东京,日本子宫内膜息肉是育龄妇女的常见病,但其分子机制尚不清楚。下一代测序仪使整个外显子组测序更容易。本研究利用新一代测序仪对子宫内膜息肉的驱动基因进行了研究。
{"title":"17th Biennial Meeting of the International Gynecologic Cancer Society Kyoto, Japan September 14-16, 2018","authors":"P. Cohen, S. Böhm, A. Powell, T. Meniawy, C. Stewart, Max K. Bulsara, C. Gilks, N. Singh","doi":"10.1097/01.IGC.0000546279.09648.02","DOIUrl":"https://doi.org/10.1097/01.IGC.0000546279.09648.02","url":null,"abstract":"Clinical medicine hopes for the development of reliable tumor markers, on the basis of which there can be chosen the optimal treatment program for uterine sarcoma patients, and also make a prognosis. The hyperexpression of PD-L1 in different tumors such as melanoma, kidney cancer, non-small cell lung cancer correlates with unfavorable prognosis of the disease. The role of PD-L1 expression, as a tumor marker in sarcoma, remains unclear. Objective. The investigation of PD-L1 expression as a prognostic tumor marker for uterine sarcoma. Methods. There have been selected 30 uterine sarcoma patients stage I-II (T1-2NxM0), for immunohistochemistry analyze of PD-L1 expression. Depending on the morphological tumor types all the patients were distributed: leiomyosarcoma (LMS) 20.0%, endometrial stromal sarcoma (ESS) 46.7%, undifferentiated sarcoma (HC) 33.3%. Results. Our results showed that 73.3 % of patients with uterine sarcoma showed a low expression level of PD-L1. The moderate level and overexpression of PD-L1 were observed in the undifferentiated and endometrial stromal sarcoma (fig.1) – in 13.3 and 6.7 %, respectively. At further follow-up of patients with PD-L1 expression, the relapse of the disease was detected in 50.0 % of cases. Conclusion. The PD-L1 expression in tumor tissue, regardless of its level, is considered to be an unfavorable prognostic factor for the uterine sarcoma patients. In case of moderate expression level of PD-L1, so as at its overexpression, the tumor progression was detected in 83.3% of uterine sarcoma patients. Fig.1. Moderate expression level of PD-L1 in ESS cells. Reaction from MCAB to PD-L1 (Clone 130021), х400. Copyright ' 2018 by IGCS and ESGO. Unauthorized reproduction of this article is prohibited. 569 Volume 28, Supplement 2, September 2018 POSTER PRESENTATIONS Gynecologic Pathology/Cytology and Disease Pathogenesis IGCS8-0522 RAS GENES IS FREQUENTLY MUTATED IN ENDOMETRIAL POLYPS T. Takeda, K. Banno, M. Yanokura, T. Takahashi, M. Anko, A. Sera, H. Kunitomi, K. Tsuji, Y. Kobayashi, E. Tominaga, D. Aoki Keio University School of Medicine, Obstetrics and Gynecology, Tokyo, Japan Background and Aims: Endometrial polyp is a common disease for women in reproductive age, however a molecular mechanism of endometrial polyp is still unclear. Next-generation sequencer makes whole exome sequencing easier. In this study, we investigated a driver gene of endometrial polyp by next-generation sequencer.","PeriodicalId":13983,"journal":{"name":"International Journal of Gynecologic Cancer","volume":"13 1","pages":"1 - 1258"},"PeriodicalIF":0.0,"publicationDate":"2018-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73888580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 11
Letter From Editor – February 2018 编辑来信- 2018年2月
Pub Date : 2018-02-01 DOI: 10.1097/IGC.0000000000001206
U. Beller
{"title":"Letter From Editor – February 2018","authors":"U. Beller","doi":"10.1097/IGC.0000000000001206","DOIUrl":"https://doi.org/10.1097/IGC.0000000000001206","url":null,"abstract":"","PeriodicalId":13983,"journal":{"name":"International Journal of Gynecologic Cancer","volume":"239 1","pages":"207 - 207"},"PeriodicalIF":0.0,"publicationDate":"2018-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74726174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Quality of Life in Women After Pelvic Exenteration for Gynecological Malignancies: A Multicentric Study. 妇科恶性肿瘤盆腔切除术后妇女的生活质量:一项多中心研究。
Pub Date : 2018-02-01 DOI: 10.1097/IGC.0000000000000612
Margherita Dessole, Marco Petrillo, Alessandro Lucidi, Angelica Naldini, Martina Rossi, Pierandrea De Iaco, Simone Marnitz, Jalid Sehouli, Giovanni Scambia, Vito Chiantera

Objectives: This retrospective, multicentric study investigates quality-of-life issues and emotional distress in gynecological cancer survivors submitted to pelvic exenteration (PE).

Methods: The Global Health Status scale of European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire (QLQ-C30; the EORTC QLQ-CX24 (CX24), and EORTC QLQ-OV28 questionnaires were administered at least 12 months from surgery only in women with no evidence of further recurrence after PE. Statistical analysis was performed by the analysis of variance (for repeated measures.

Results: Ninety-six subjects affected by gynecological malignancies receiving PE were enrolled in the study. Anterior PE was performed in 47 patients (49%), posterior PE was performed in 29 cases (30.2%), and total PE performed in 20 women (20.8%). In 38 cases (39.6%), a definitive colostomy was performed. Urinary diversion with continent pouch was created in 11 patients. (11.5%), whereas in the remaining cases, a noncontinent pouch was reconstructed. Patients showed a significant discomfort in attitude to disease (71.5 ± 4.7), body image (48.9 ± 6.4), financial difficulties (56.2 ± 5.8), gastrointestinal symptoms (constipation, 47.8 ± 5.1; diarrhea, 62.4 ± 6.6; appetite loss, 43.6 ± 6.7), insomnia (64.5 ± 6.6), Global Health Status (64.6 ± 3.8), physical functioning (65.8 ± 4.6), role functioning (58.8 ± 5.8), and emotional functioning (67.4 ± 4.2). A higher number of ostomies (hazard rate [HR], 7.613; P = 0.012), the creation of a noncontinent bladder (HR, 8.230; P = 0.009), and of definitive colostomy (HR, 8.516; P = 0.008) emerged as independent predictors of poorer Global Health Status scores. Older age (HR, 11.235; P = 0.003), vaginal/vulvar cancer (HR, 7.369; P = 0.013), total/posterior PE (HR, 7.393; P = 0.013), higher number of ostomies (HR, 7.613; P = 0.012), the creation of a noncontinent bladder (HR, 8.230; P = 0.009), and of definitive colostomy (HR, 8.516; P = 0.008) emerged as independent predictors of lower body image levels.

Conclusions: Long-term psycho-oncological support is strongly recommended. The reduction of ostomies seems the most effective way to improve patients' quality of life.

目的:本回顾性、多中心研究调查盆腔切除(PE)后妇科癌症幸存者的生活质量问题和情绪困扰。方法:采用欧洲癌症研究与治疗组织(EORTC)全球健康状况量表核心生活质量问卷(QLQ-C30);EORTC QLQ-CX24 (CX24)和EORTC QLQ-OV28问卷调查仅用于术后至少12个月无PE后进一步复发证据的女性。采用方差分析(重复测量)进行统计分析。结果:96例接受PE治疗的妇科恶性肿瘤患者被纳入研究。47例(49%)患者行前路PE, 29例(30.2%)患者行后路PE, 20例(20.8%)患者行全路PE。38例(39.6%)最终行结肠造口术。11例患者采用尿袋引流。(11.5%),而在其余病例中,非大陆袋被重建。患者在疾病态度(71.5±4.7)、身体形象(48.9±6.4)、经济困难(56.2±5.8)、胃肠道症状(便秘,47.8±5.1;腹泻,62.4±6.6;食欲减退(43.6±6.7)、失眠(64.5±6.6)、整体健康状况(64.6±3.8)、身体功能(65.8±4.6)、角色功能(58.8±5.8)和情绪功能(67.4±4.2)。造口次数较高(危险率[HR], 7.613;P = 0.012),膀胱失禁(HR, 8.230;P = 0.009)和最终结肠造口术(HR, 8.516;P = 0.008)成为较差的全球健康状况评分的独立预测因子。老年(HR, 11.235;P = 0.003),阴道/外阴癌(HR, 7.369;P = 0.013),总PE /后侧PE (HR, 7.393;P = 0.013),较高的造口率(HR, 7.613;P = 0.012),膀胱失禁(HR, 8.230;P = 0.009)和最终结肠造口术(HR, 8.516;P = 0.008)成为较低身体形象水平的独立预测因子。结论:强烈推荐长期的心理肿瘤支持。减少造口手术似乎是改善患者生活质量的最有效方法。
{"title":"Quality of Life in Women After Pelvic Exenteration for Gynecological Malignancies: A Multicentric Study.","authors":"Margherita Dessole, Marco Petrillo, Alessandro Lucidi, Angelica Naldini, Martina Rossi, Pierandrea De Iaco, Simone Marnitz, Jalid Sehouli, Giovanni Scambia, Vito Chiantera","doi":"10.1097/IGC.0000000000000612","DOIUrl":"10.1097/IGC.0000000000000612","url":null,"abstract":"<p><strong>Objectives: </strong>This retrospective, multicentric study investigates quality-of-life issues and emotional distress in gynecological cancer survivors submitted to pelvic exenteration (PE).</p><p><strong>Methods: </strong>The Global Health Status scale of European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire (QLQ-C30; the EORTC QLQ-CX24 (CX24), and EORTC QLQ-OV28 questionnaires were administered at least 12 months from surgery only in women with no evidence of further recurrence after PE. Statistical analysis was performed by the analysis of variance (for repeated measures.</p><p><strong>Results: </strong>Ninety-six subjects affected by gynecological malignancies receiving PE were enrolled in the study. Anterior PE was performed in 47 patients (49%), posterior PE was performed in 29 cases (30.2%), and total PE performed in 20 women (20.8%). In 38 cases (39.6%), a definitive colostomy was performed. Urinary diversion with continent pouch was created in 11 patients. (11.5%), whereas in the remaining cases, a noncontinent pouch was reconstructed. Patients showed a significant discomfort in attitude to disease (71.5 ± 4.7), body image (48.9 ± 6.4), financial difficulties (56.2 ± 5.8), gastrointestinal symptoms (constipation, 47.8 ± 5.1; diarrhea, 62.4 ± 6.6; appetite loss, 43.6 ± 6.7), insomnia (64.5 ± 6.6), Global Health Status (64.6 ± 3.8), physical functioning (65.8 ± 4.6), role functioning (58.8 ± 5.8), and emotional functioning (67.4 ± 4.2). A higher number of ostomies (hazard rate [HR], 7.613; P = 0.012), the creation of a noncontinent bladder (HR, 8.230; P = 0.009), and of definitive colostomy (HR, 8.516; P = 0.008) emerged as independent predictors of poorer Global Health Status scores. Older age (HR, 11.235; P = 0.003), vaginal/vulvar cancer (HR, 7.369; P = 0.013), total/posterior PE (HR, 7.393; P = 0.013), higher number of ostomies (HR, 7.613; P = 0.012), the creation of a noncontinent bladder (HR, 8.230; P = 0.009), and of definitive colostomy (HR, 8.516; P = 0.008) emerged as independent predictors of lower body image levels.</p><p><strong>Conclusions: </strong>Long-term psycho-oncological support is strongly recommended. The reduction of ostomies seems the most effective way to improve patients' quality of life.</p>","PeriodicalId":13983,"journal":{"name":"International Journal of Gynecologic Cancer","volume":"23 1","pages":"267-273"},"PeriodicalIF":0.0,"publicationDate":"2018-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76526915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pazopanib Maintenance Therapy in East Asian Women With Advanced Epithelial Ovarian Cancer: Results From AGO-OVAR16 and an East Asian Study. 帕唑帕尼维持治疗东亚晚期上皮性卵巢癌妇女:AGO-OVAR16和东亚研究的结果
Pub Date : 2018-01-01 DOI: 10.1097/IGC.0000000000000602
Jae-Weon Kim, Sven Mahner, Ling-Ying Wu, Tadahiro Shoji, Byoung-Gie Kim, Jian-Qing Zhu, Tadao Takano, Sang-Yoon Park, Bei-Hua Kong, Qiang Wu, Kung-Liahng Wang, Hextan Ys Ngan, Ji-Hong Liu, Li-Hui Wei, Ionel Mitrica, Pingkuan Zhang, Rocco Crescenzo, Qiong Wang, Charles J Cox, Philipp Harter, Andreas du Bois

Objective: The recent phase 3 trial AGO-OVAR16 demonstrated that pazopanib maintenance improved median progression-free survival in patients with ovarian cancer whose disease did not progress during first-line treatment. However, this improvement was not seen in the subset of East Asian patients. The current analysis evaluated the efficacy and safety of pazopanib maintenance in East Asian patients from AGO-OVAR16 and a separate East Asian study.

Materials and methods: East Asian patients from AGO-OVAR16 (n = 209) and the East Asian study (N = 145) were randomized 1:1 to receive pazopanib 800 mg/d or placebo for up to 24 months. The primary end point for each study was progression-free survival by RECIST (Response Evaluation Criteria in Solid Tumors) based on investigator assessment. Clinical and genetics data were analyzed separately by study or pooled according to separate predetermined statistical plans.

Results: Pazopanib maintenance had a detrimental effect on median progression-free survival versus placebo in East Asian patients from the combined studies (n = 354; 17.9 vs 21.5 months; hazard ratio, 1.114; 95% confidence interval, 0.818-1.518; P = 0.4928). Pazopanib maintenance showed a disadvantage in overall survival in East Asian patients from AGO-OVAR16 versus placebo (hazard ratio, 1.706; 95% confidence interval, 1.010-2.883; P = 0.0465); overall survival analysis was not performed in the East Asian study because of insufficient event numbers. Pazopanib-treated patients had a significantly higher incidence of grade 3 or higher hypertension (27%) and neutropenia (13%) versus placebo.

Conclusions: The treatment effect of maintenance pazopanib in East Asian patients seemed to differ from that in non-Asian patients. In study-specific and pooled analyses, none of the potential factors analyzed could satisfactorily explain the different efficacy results of pazopanib in East Asian patients.

目的:最近的3期试验AGO-OVAR16表明,帕唑帕尼维持可改善一线治疗期间疾病未进展的卵巢癌患者的中位无进展生存期。然而,这种改善在东亚患者亚群中未见。目前的分析评估了来自AGO-OVAR16和另一项东亚研究的东亚患者维持帕唑帕尼的有效性和安全性。材料和方法:来自AGO-OVAR16 (n = 209)和东亚研究(n = 145)的东亚患者按1:1随机分配,接受帕唑帕尼800 mg/d或安慰剂治疗,最长24个月。每项研究的主要终点都是基于研究者评估的RECIST(实体肿瘤反应评价标准)的无进展生存期。临床和遗传学数据分别通过研究进行分析或根据单独的预定统计计划进行汇总。结果:在联合研究的东亚患者中,维持帕唑帕尼对安慰剂的中位无进展生存期有不利影响(n = 354;17.9 vs 21.5个月;风险比为1.114;95%置信区间为0.818-1.518;P = 0.4928)。与安慰剂相比,帕唑帕尼维持在东亚AGO-OVAR16患者的总生存期中处于劣势(风险比,1.706;95%置信区间为1.010-2.883;P = 0.0465);由于事件数量不足,东亚研究未进行总体生存分析。与安慰剂相比,pazopanib治疗的患者3级或更高级别高血压(27%)和中性粒细胞减少症(13%)的发生率明显更高。结论:维持帕唑帕尼在东亚患者中的治疗效果似乎与非亚洲患者有所不同。在研究特异性和汇总分析中,分析的所有潜在因素都不能令人满意地解释帕唑帕尼在东亚患者中的不同疗效结果。
{"title":"Pazopanib Maintenance Therapy in East Asian Women With Advanced Epithelial Ovarian Cancer: Results From AGO-OVAR16 and an East Asian Study.","authors":"Jae-Weon Kim, Sven Mahner, Ling-Ying Wu, Tadahiro Shoji, Byoung-Gie Kim, Jian-Qing Zhu, Tadao Takano, Sang-Yoon Park, Bei-Hua Kong, Qiang Wu, Kung-Liahng Wang, Hextan Ys Ngan, Ji-Hong Liu, Li-Hui Wei, Ionel Mitrica, Pingkuan Zhang, Rocco Crescenzo, Qiong Wang, Charles J Cox, Philipp Harter, Andreas du Bois","doi":"10.1097/IGC.0000000000000602","DOIUrl":"10.1097/IGC.0000000000000602","url":null,"abstract":"<p><strong>Objective: </strong>The recent phase 3 trial AGO-OVAR16 demonstrated that pazopanib maintenance improved median progression-free survival in patients with ovarian cancer whose disease did not progress during first-line treatment. However, this improvement was not seen in the subset of East Asian patients. The current analysis evaluated the efficacy and safety of pazopanib maintenance in East Asian patients from AGO-OVAR16 and a separate East Asian study.</p><p><strong>Materials and methods: </strong>East Asian patients from AGO-OVAR16 (n = 209) and the East Asian study (N = 145) were randomized 1:1 to receive pazopanib 800 mg/d or placebo for up to 24 months. The primary end point for each study was progression-free survival by RECIST (Response Evaluation Criteria in Solid Tumors) based on investigator assessment. Clinical and genetics data were analyzed separately by study or pooled according to separate predetermined statistical plans.</p><p><strong>Results: </strong>Pazopanib maintenance had a detrimental effect on median progression-free survival versus placebo in East Asian patients from the combined studies (n = 354; 17.9 vs 21.5 months; hazard ratio, 1.114; 95% confidence interval, 0.818-1.518; P = 0.4928). Pazopanib maintenance showed a disadvantage in overall survival in East Asian patients from AGO-OVAR16 versus placebo (hazard ratio, 1.706; 95% confidence interval, 1.010-2.883; P = 0.0465); overall survival analysis was not performed in the East Asian study because of insufficient event numbers. Pazopanib-treated patients had a significantly higher incidence of grade 3 or higher hypertension (27%) and neutropenia (13%) versus placebo.</p><p><strong>Conclusions: </strong>The treatment effect of maintenance pazopanib in East Asian patients seemed to differ from that in non-Asian patients. In study-specific and pooled analyses, none of the potential factors analyzed could satisfactorily explain the different efficacy results of pazopanib in East Asian patients.</p>","PeriodicalId":13983,"journal":{"name":"International Journal of Gynecologic Cancer","volume":"53 1","pages":"2-10"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73345829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Surgical Outcomes of Patients Undergoing Extrafascial Hysterectomy After Neoadjuvant Radiotherapy With or Without Chemotherapy for Locally Advanced Endometrial Cancer Clinically Extending to the Cervix or Parametria. 局部晚期子宫内膜癌经新辅助放疗伴或不伴化疗后行筋膜外子宫切除术患者的手术效果
Pub Date : 2017-07-01 DOI: 10.1097/IGC.0000000000000614
Michelle M Boisen, J Austin Vargo, Sushi Beriwal, Paniti Sukumvanich, Alexander B Olawaiye, Joseph L Kelley, Robert P Edwards, Marilyn Huang, Madeleine Courtney-Brooks, John T Comerci

Objectives: Recent data have shown high rates of clinical and pathologic responses to neoadjuvant radiation therapy for locally advanced endometrial cancer. There are limited data on the surgical outcomes of these patients in the era of modern radiation and surgical techniques. We sought to characterize surgical outcomes after extrafascial hysterectomy in this population.

Methods: Patients with endometrial cancer of all histologies clinically involving the cervix or parametria treated with neoadjuvant brachytherapy followed by extrafascial hysterectomy from 1999 to 2014 were identified. Patient charts were reviewed for data regarding treatment characteristics and postoperative outcomes. Pearson χ and logistic regression analyses were used to assess correlations between surgical complications and treatment-related variables.

Results: Twenty-nine patients met inclusion criteria. Mean operating time for the cohort was 115 minutes. Mean estimated blood loss was 100 mL. No visceral injuries occurred. Mean length of hospital stay was 1 and 4 days for the minimally invasive and laparotomy groups, respectively. Rates of postoperative ileus, blood transfusion, wound infection, and readmission were 3%, 3%, 6%, and 3%, respectively. No case of prolonged urodynamic dysfunction was noted. The rate of vaginal complications was significantly higher in the group of patients who underwent minimally invasive surgery as compared with laparotomy (33% vs 5%, P < 0.041).

Conclusions: These data support adjuvant extrafascial hysterectomy after neoadjuvant radiotherapy for endometrial cancer with cervical or parametrial involvement as a safe and viable procedure, with low rates of postoperative complications. Extra care should be taken when closing the vaginal cuff to reduce the risk of vaginal cuff complications.

目的:最近的数据显示,局部晚期子宫内膜癌新辅助放射治疗的临床和病理反应率很高。在现代放射和外科技术时代,这些患者的手术结果数据有限。我们试图描述这一人群筋膜外子宫切除术后的手术结果。方法:选取1999年~ 2014年经新辅助近距离放射治疗并筋膜外子宫切除术的所有组织学的临床累及子宫颈或参数的子宫内膜癌患者。回顾患者病历,了解治疗特点和术后结果。采用Pearson χ和logistic回归分析评估手术并发症与治疗相关变量之间的相关性。结果:29例患者符合纳入标准。该队列的平均手术时间为115分钟。平均估计失血量为100毫升,未发生内脏损伤。微创组和剖腹手术组的平均住院时间分别为1天和4天。术后肠梗阻、输血、伤口感染和再入院率分别为3%、3%、6%和3%。没有发现长期尿动力障碍的病例。微创手术组阴道并发症发生率明显高于剖腹手术组(33% vs 5%, P < 0.041)。结论:这些数据支持新辅助放疗后伴有宫颈或旁系累及的子宫内膜癌行筋膜外子宫切除术是一种安全可行的手术,术后并发症发生率低。闭合阴道袖带时应格外小心,以减少阴道袖带并发症的风险。
{"title":"Surgical Outcomes of Patients Undergoing Extrafascial Hysterectomy After Neoadjuvant Radiotherapy With or Without Chemotherapy for Locally Advanced Endometrial Cancer Clinically Extending to the Cervix or Parametria.","authors":"Michelle M Boisen, J Austin Vargo, Sushi Beriwal, Paniti Sukumvanich, Alexander B Olawaiye, Joseph L Kelley, Robert P Edwards, Marilyn Huang, Madeleine Courtney-Brooks, John T Comerci","doi":"10.1097/IGC.0000000000000614","DOIUrl":"10.1097/IGC.0000000000000614","url":null,"abstract":"<p><strong>Objectives: </strong>Recent data have shown high rates of clinical and pathologic responses to neoadjuvant radiation therapy for locally advanced endometrial cancer. There are limited data on the surgical outcomes of these patients in the era of modern radiation and surgical techniques. We sought to characterize surgical outcomes after extrafascial hysterectomy in this population.</p><p><strong>Methods: </strong>Patients with endometrial cancer of all histologies clinically involving the cervix or parametria treated with neoadjuvant brachytherapy followed by extrafascial hysterectomy from 1999 to 2014 were identified. Patient charts were reviewed for data regarding treatment characteristics and postoperative outcomes. Pearson χ and logistic regression analyses were used to assess correlations between surgical complications and treatment-related variables.</p><p><strong>Results: </strong>Twenty-nine patients met inclusion criteria. Mean operating time for the cohort was 115 minutes. Mean estimated blood loss was 100 mL. No visceral injuries occurred. Mean length of hospital stay was 1 and 4 days for the minimally invasive and laparotomy groups, respectively. Rates of postoperative ileus, blood transfusion, wound infection, and readmission were 3%, 3%, 6%, and 3%, respectively. No case of prolonged urodynamic dysfunction was noted. The rate of vaginal complications was significantly higher in the group of patients who underwent minimally invasive surgery as compared with laparotomy (33% vs 5%, P < 0.041).</p><p><strong>Conclusions: </strong>These data support adjuvant extrafascial hysterectomy after neoadjuvant radiotherapy for endometrial cancer with cervical or parametrial involvement as a safe and viable procedure, with low rates of postoperative complications. Extra care should be taken when closing the vaginal cuff to reduce the risk of vaginal cuff complications.</p>","PeriodicalId":13983,"journal":{"name":"International Journal of Gynecologic Cancer","volume":"39 1","pages":"1149-1154"},"PeriodicalIF":0.0,"publicationDate":"2017-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88252648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Serous Tubal Intraepithelial Carcinoma Associated With Extraovarian Metastases. 浆液性输卵管上皮内癌伴卵巢外转移。
Pub Date : 2017-03-01 DOI: 10.1097/IGC.0000000000000920
Stephanie Schneider, Sebastian Heikaus, Philipp Harter, Florian Heitz, Christoph Grimm, Beyhan Ataseven, Sonia Prader, Christian Kurzeder, Thomas Ebel, Alexander Traut, Andreas du Bois

Objective: The evolving knowledge of ovarian carcinogenesis sets the stage for our understanding of high-grade serous pelvic carcinoma (HGSC). Findings in prophylactic surgery introduced serous tubal intraepithelial carcinoma (STIC) as potential precursor of HGSC. The present study explores whether STIC instead should already be considered as an early stage of HGSC with a need for comprehensive staging and therapy.

Patients and methods: We identified all consecutive patients with HGSC who received first-line therapy in our referral center for gynecologic oncology from January 2011 to April 2016. All chemo-naive patients with upfront debulking surgery in whom an association of STIC and tumor lesions could be analyzed were included. Patients with previous removal of the adnexa or overgrown of the fallopian tube by the tumor were excluded. Pathological workup of the fallopian tubes according to the SEE-FIM protocol was conducted.

Results: We analyzed a series of 231 consecutive patients with HGSC of whom 121 (52.4%) had ovarian cancer, 74 (32.0%) had cancer of the fallopian tubes and 36 patients (15.6%) had primary peritoneal cancer. Serous tubal intraepithelial carcinoma could be identified in 158 (68.4%) of 231 patients; of 22 patients, 28.1% is ovarian cancer, 30.8% cancer of the fallopian tubes, and 9.5% peritoneal cancer. Four patients without any further intra-abdominal disease were identified of whom 2 patients had stage FIGO IA and 2 patients had lymph node metastases only.

Conclusions: Our data suggest that STIC should be regarded as a malignant lesion with metastatic potential. Therefore, we recommend a comprehensive surgical staging including lymphadenectomy.

目的:不断发展的对卵巢癌发生的认识为我们理解高级别浆液性盆腔癌(HGSC)奠定了基础。预防性手术发现浆液性输卵管上皮内癌(STIC)是HGSC的潜在前体。目前的研究探讨了STIC是否应该被视为HGSC的早期阶段,需要综合分期和治疗。患者和方法:我们选取了2011年1月至2016年4月在我们妇科肿瘤转诊中心接受一线治疗的所有连续HGSC患者。所有接受前期减容手术的化疗初治患者均包括在内,其中STIC与肿瘤病变的关系可以被分析。既往因肿瘤切除附件或输卵管过度生长的患者排除在外。按照SEE-FIM方案对输卵管进行病理检查。结果:我们分析了231例连续的HGSC患者,其中121例(52.4%)患有卵巢癌,74例(32.0%)患有输卵管癌,36例(15.6%)患有原发性腹膜癌。231例患者中有158例(68.4%)可确诊浆液性输卵管上皮内癌;在22例患者中,28.1%为卵巢癌,30.8%为输卵管癌,9.5%为腹膜癌。4例患者无进一步腹内疾病,其中2例为FIGO IA期,2例仅为淋巴结转移。结论:我们的数据表明STIC应被视为具有转移潜力的恶性病变。因此,我们建议综合手术分期,包括淋巴结切除术。
{"title":"Serous Tubal Intraepithelial Carcinoma Associated With Extraovarian Metastases.","authors":"Stephanie Schneider, Sebastian Heikaus, Philipp Harter, Florian Heitz, Christoph Grimm, Beyhan Ataseven, Sonia Prader, Christian Kurzeder, Thomas Ebel, Alexander Traut, Andreas du Bois","doi":"10.1097/IGC.0000000000000920","DOIUrl":"10.1097/IGC.0000000000000920","url":null,"abstract":"<p><strong>Objective: </strong>The evolving knowledge of ovarian carcinogenesis sets the stage for our understanding of high-grade serous pelvic carcinoma (HGSC). Findings in prophylactic surgery introduced serous tubal intraepithelial carcinoma (STIC) as potential precursor of HGSC. The present study explores whether STIC instead should already be considered as an early stage of HGSC with a need for comprehensive staging and therapy.</p><p><strong>Patients and methods: </strong>We identified all consecutive patients with HGSC who received first-line therapy in our referral center for gynecologic oncology from January 2011 to April 2016. All chemo-naive patients with upfront debulking surgery in whom an association of STIC and tumor lesions could be analyzed were included. Patients with previous removal of the adnexa or overgrown of the fallopian tube by the tumor were excluded. Pathological workup of the fallopian tubes according to the SEE-FIM protocol was conducted.</p><p><strong>Results: </strong>We analyzed a series of 231 consecutive patients with HGSC of whom 121 (52.4%) had ovarian cancer, 74 (32.0%) had cancer of the fallopian tubes and 36 patients (15.6%) had primary peritoneal cancer. Serous tubal intraepithelial carcinoma could be identified in 158 (68.4%) of 231 patients; of 22 patients, 28.1% is ovarian cancer, 30.8% cancer of the fallopian tubes, and 9.5% peritoneal cancer. Four patients without any further intra-abdominal disease were identified of whom 2 patients had stage FIGO IA and 2 patients had lymph node metastases only.</p><p><strong>Conclusions: </strong>Our data suggest that STIC should be regarded as a malignant lesion with metastatic potential. Therefore, we recommend a comprehensive surgical staging including lymphadenectomy.</p>","PeriodicalId":13983,"journal":{"name":"International Journal of Gynecologic Cancer","volume":"21 1","pages":"444-451"},"PeriodicalIF":0.0,"publicationDate":"2017-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85391308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Morbidity of Staging Inframesenteric Paraaortic Lymphadenectomy in Locally Advanced Cervical Cancer Compared With Infrarenal Lymphadenectomy. 局部晚期宫颈癌肠下主动脉旁淋巴结切除术与肾下淋巴结切除术的分期比较。
Pub Date : 2017-03-01 DOI: 10.1097/IGC.0000000000000921
Clothilde Petitnicolas, Henri Azaïs, Louise Ghesquière, Emmanuelle Tresch-Bruneel, Abel Cordoba, Fabrice Narducci, Lucie Bresson, Eric Leblanc

Objective: Extended-field chemoradiation is typically used for the management of patients with locally advanced cervical cancer. Given the low rate of skipped metastases above the inferior mesenteric artery, ilioinframesenteric dissection seems to be an acceptable pattern of paraaortic lymph node dissection (LND). Our objective is to compare the surgical morbidity of inframesenteric LND (IM-LND) with infrarenal LND (IR-LND).

Methods: In our center, all of the patients with locally advanced cervical cancer and negative magnetic resonance imaging and positron emission tomography-computed tomography imaging at the paraaortic level were offered laparoscopic staging including a diagnostic laparoscopy followed, if negative, by an extraperitoneal paraaortic lymphadenectomy. From January 2011 to September 2015, we included patients who had paraaortic LND from both common iliac bifurcations and divided them into 2 groups according to dissection pattern: to the inferior mesenteric artery (IM-LND) level or to the left renal vein (IR-LND) level. The perioperative and postoperative data were retrospectively recorded.

Results: A total of 119 women were included in our study: 56 in the IM-LND group and 63 in the IR-LND group. There was no difference in the patients' characteristics between groups. Regarding the surgical procedure, the operating time was shorter in the IM-LND group than the IR-LND group, 174 ± 50 minutes versus 209 ± 61 minutes (P = 0.001), respectively. There was no significant difference in intra- and postoperative complications, overall survival, or progression-free survival.

Conclusions: In our series, exclusive IM-LND surgery is faster than IR-LND and results in similar morbidity and survival rates. These results confirm the feasibility and the applicability of IM-LND to simplify the surgical procedure without impacting survival. More patients should be included in the study to demonstrate the lower rate of morbidity.

目的:大范围放化疗是治疗局部晚期宫颈癌的常用方法。考虑到肠系膜下动脉上方的低转移率,髂肠系膜下夹层似乎是一种可接受的主动脉旁淋巴结清扫(LND)模式。我们的目的是比较肠下LND (IM-LND)和肾下LND (IR-LND)的手术发病率。方法:本中心对所有局部晚期宫颈癌患者进行腹腔镜分期,包括诊断性腹腔镜检查,如果阴性,则行腹腔外主动脉旁淋巴结切除术。从2011年1月至2015年9月,我们纳入了来自两个髂常见分支的主动脉旁LND患者,并根据剥离模式分为2组:至肠系膜下动脉(IM-LND)水平或至左肾静脉(IR-LND)水平。回顾性记录围手术期和术后资料。结果:我们的研究共纳入119名女性:IM-LND组56名,IR-LND组63名。两组患者的特征无明显差异。在手术过程中,IM-LND组的手术时间较IR-LND组短,分别为174±50分钟和209±61分钟(P = 0.001)。在手术内和术后并发症、总生存期或无进展生存期方面没有显著差异。结论:在我们的研究中,单独的IM-LND手术比IR-LND更快,其发病率和生存率相似。这些结果证实了IM-LND在不影响生存的情况下简化手术程序的可行性和适用性。研究中应纳入更多的患者,以证明发病率较低。
{"title":"Morbidity of Staging Inframesenteric Paraaortic Lymphadenectomy in Locally Advanced Cervical Cancer Compared With Infrarenal Lymphadenectomy.","authors":"Clothilde Petitnicolas, Henri Azaïs, Louise Ghesquière, Emmanuelle Tresch-Bruneel, Abel Cordoba, Fabrice Narducci, Lucie Bresson, Eric Leblanc","doi":"10.1097/IGC.0000000000000921","DOIUrl":"10.1097/IGC.0000000000000921","url":null,"abstract":"<p><strong>Objective: </strong>Extended-field chemoradiation is typically used for the management of patients with locally advanced cervical cancer. Given the low rate of skipped metastases above the inferior mesenteric artery, ilioinframesenteric dissection seems to be an acceptable pattern of paraaortic lymph node dissection (LND). Our objective is to compare the surgical morbidity of inframesenteric LND (IM-LND) with infrarenal LND (IR-LND).</p><p><strong>Methods: </strong>In our center, all of the patients with locally advanced cervical cancer and negative magnetic resonance imaging and positron emission tomography-computed tomography imaging at the paraaortic level were offered laparoscopic staging including a diagnostic laparoscopy followed, if negative, by an extraperitoneal paraaortic lymphadenectomy. From January 2011 to September 2015, we included patients who had paraaortic LND from both common iliac bifurcations and divided them into 2 groups according to dissection pattern: to the inferior mesenteric artery (IM-LND) level or to the left renal vein (IR-LND) level. The perioperative and postoperative data were retrospectively recorded.</p><p><strong>Results: </strong>A total of 119 women were included in our study: 56 in the IM-LND group and 63 in the IR-LND group. There was no difference in the patients' characteristics between groups. Regarding the surgical procedure, the operating time was shorter in the IM-LND group than the IR-LND group, 174 ± 50 minutes versus 209 ± 61 minutes (P = 0.001), respectively. There was no significant difference in intra- and postoperative complications, overall survival, or progression-free survival.</p><p><strong>Conclusions: </strong>In our series, exclusive IM-LND surgery is faster than IR-LND and results in similar morbidity and survival rates. These results confirm the feasibility and the applicability of IM-LND to simplify the surgical procedure without impacting survival. More patients should be included in the study to demonstrate the lower rate of morbidity.</p>","PeriodicalId":13983,"journal":{"name":"International Journal of Gynecologic Cancer","volume":"15 1","pages":"575-580"},"PeriodicalIF":0.0,"publicationDate":"2017-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88242208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
International Journal of Gynecologic Cancer
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1